Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Rittmeyer

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Cancers|June 10, 2023
Tobias Raphael Overbeck, Annika Reiffert, Katja Schmitz, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Oncology Research and Treatment|April 7, 2025
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi ConsensusPhilipp Ivanyi, Bernd Alt-Epping, Lars Bullinger, et al.
Clinical Medicine Insights. Oncology|September 5, 2020
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor KineticsLaurent Claret, Jin Y Jin, Charles Ferté, et al.
Translational Lung Cancer Research|August 25, 2021
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Translational Lung Cancer Research|July 18, 2020
Top-level <i>MET</i> gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosisTobias Raphael Overbeck, Dana Alina Cron, Katja Schmitz, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2021
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)Amanda Tufman, Jens Neumann, Farkhad Manapov, et al.
Clinical Lung Cancer|July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK TrialShirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cancers|June 10, 2023
Tobias Raphael Overbeck, Annika Reiffert, Katja Schmitz, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Oncology Research and Treatment|April 7, 2025
Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi ConsensusPhilipp Ivanyi, Bernd Alt-Epping, Lars Bullinger, et al.
Clinical Medicine Insights. Oncology|September 5, 2020
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Lung Cancer (Amsterdam, Netherlands)|February 15, 2026
Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trialMartin Reck, Cornelius Waller, Parvis Sadjadian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor KineticsLaurent Claret, Jin Y Jin, Charles Ferté, et al.
Translational Lung Cancer Research|August 25, 2021
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Translational Lung Cancer Research|July 18, 2020
Top-level <i>MET</i> gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosisTobias Raphael Overbeck, Dana Alina Cron, Katja Schmitz, et al.
Lung Cancer (Amsterdam, Netherlands)|August 9, 2021
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)Amanda Tufman, Jens Neumann, Farkhad Manapov, et al.
Clinical Lung Cancer|July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK TrialShirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Pageof 6